Prime Medicine, Inc. announced the appointment of Allan Reine, M.D., as the Company?s Chief Financial Officer, effective January 17, 2024. Dr. Reine, age 49, a seasoned financial executive with over twenty years? experience in the biotechnology industry, Dr. Reine will be responsible for the company?s financing strategy and investor relations, and will oversee all financial operations as Prime Medicine begins its transition into a clinical company.

Prior to joining Prime Medicine, Dr. Reine was Chief Financial Officer at Foghorn Therapeutics and, before that, at Pieris Pharmaceuticals. Dr. Reine also serves as Chairman of the Board of ONK Therapeutics. Previously, Dr. Reine managed various healthcare portfolios primarily focused on biotechnology and pharmaceutical companies at Lombard Odier Asset Management, Citi Principal Strategies, SAC Capital, Trivium Capital and Alexandra Investment Management.

He started his career at CIBC World Markets where he worked in both biotechnology investment banking and biotechnology equity research. Dr. Reine received his M.D. from the University of Toronto, and his Bachelor of Science in statistical sciences from the University of Western Ontario. Effective January 17, 2024, Carman Alenson will transition from Interim Chief Financial Officer and Chief Accounting Officer to Senior Vice President, Finance and Chief Accounting Officer.

She will step down from the role of principal financial officer and will continue in her role of principal accounting officer.